TY - JOUR
T1 - Prolactin response to thyrotropin-releasing hormone (TRH) in patients with hypothalamic-pituitary disease
AU - Barbieri, R. L.
AU - Cooper, D. S.
AU - Daniels, G. H.
AU - Nathan, D.
AU - Klibanski, A.
AU - Ridgway, E. C.
PY - 1985
Y1 - 1985
N2 - The prolactin (PRL) response to thyrotropin-releasing hormone (TRH) was evaluated in 686 patients over a 4-year period. Of the 170 control subjects tested, none had a blunted PRL response to TRH. Eighty patients with prolactinomas documented by surgery were tested. Ninety-five percent (76 of 80) of these patients had an abnormally blunted PRL response to TRH. Of the 87 patients with a prolactinoma who did not undergo surgery, 98% (85 of 87) had a blunted PRL response to TRH. Many patients with other pituitary and hypothalamic diseases (pituitary tumors other than prolactinomas [Cushing's disease, acromegaly, chromophobe adenoma], craniopharyngioma) also had an abnormal PRL response to TRH (79 of 153, 52%). In the majority of patients with hyperprolactinemia due to dopamine antagonist medications, TRH stimulation did not produce a normal rise in PRL. The TRH test may be helpful in confirming the diagnosis of prolactinoma, but it is not a decisive factor in the diagnosis or management of this entity.
AB - The prolactin (PRL) response to thyrotropin-releasing hormone (TRH) was evaluated in 686 patients over a 4-year period. Of the 170 control subjects tested, none had a blunted PRL response to TRH. Eighty patients with prolactinomas documented by surgery were tested. Ninety-five percent (76 of 80) of these patients had an abnormally blunted PRL response to TRH. Of the 87 patients with a prolactinoma who did not undergo surgery, 98% (85 of 87) had a blunted PRL response to TRH. Many patients with other pituitary and hypothalamic diseases (pituitary tumors other than prolactinomas [Cushing's disease, acromegaly, chromophobe adenoma], craniopharyngioma) also had an abnormal PRL response to TRH (79 of 153, 52%). In the majority of patients with hyperprolactinemia due to dopamine antagonist medications, TRH stimulation did not produce a normal rise in PRL. The TRH test may be helpful in confirming the diagnosis of prolactinoma, but it is not a decisive factor in the diagnosis or management of this entity.
UR - http://www.scopus.com/inward/record.url?scp=0022000738&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022000738&partnerID=8YFLogxK
U2 - 10.1016/s0015-0282(16)48319-6
DO - 10.1016/s0015-0282(16)48319-6
M3 - Article
C2 - 3917409
AN - SCOPUS:0022000738
VL - 43
SP - 66
EP - 73
JO - Fertility and Sterility
JF - Fertility and Sterility
SN - 0015-0282
IS - 1
ER -